Business Description
Teva Pharmaceutical Industries Ltd
ISIN : US8816242098
Share Class Description:
TEVA: ADRTotal Employee Number:
32,842Compare
Compare
Traded in other countries / regions
TEVA.IsraelTEVA.USA0LER.UKTEV.GermanyTEVA N.MexicoT1EV34.BrazilTEVA.AustriaTEV.Bulgaria Index Membership
MSCI World IndexNASDAQ 100 IPO Date
1982-02-16Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.22 | |||||
Equity-to-Asset | 0.2 | |||||
Debt-to-Equity | 2.18 | |||||
Debt-to-EBITDA | 6.67 | |||||
Interest Coverage | 3.9 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 0.81 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.3 | |||||
3-Year EPS without NRI Growth Rate | 5.2 | |||||
3-Year FCF Growth Rate | 1.7 | |||||
3-Year Book Growth Rate | -0.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1.98 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.68 | |||||
9-Day RSI | 55.37 | |||||
14-Day RSI | 55.87 | |||||
3-1 Month Momentum % | 5.56 | |||||
6-1 Month Momentum % | 19.72 | |||||
12-1 Month Momentum % | 83.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.88 | |||||
Quick Ratio | 0.67 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 145.45 | |||||
Days Sales Outstanding | 75.76 | |||||
Days Payable | 112.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 2.26 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.47 | |||||
Operating Margin % | 18.78 | |||||
Net Margin % | 4.08 | |||||
EBITDA Margin % | 14.61 | |||||
FCF Margin % | 7.79 | |||||
OCF Margin % | 10.96 | |||||
ROE % | 9.3 | |||||
ROA % | 1.76 | |||||
ROIC % | 9.23 | |||||
3-Year ROIIC % | -41.57 | |||||
ROC (Joel Greenblatt) % | 33 | |||||
ROCE % | 5.72 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 61.1 | |||||
Forward PE Ratio | 12.11 | |||||
PE Ratio without NRI | 16.02 | |||||
PS Ratio | 2.48 | |||||
PB Ratio | 5.51 | |||||
Price-to-Free-Cash-Flow | 31.8 | |||||
Price-to-Operating-Cash-Flow | 22.6 | |||||
EV-to-EBIT | 36.5 | |||||
EV-to-Forward-EBIT | 17.3 | |||||
EV-to-EBITDA | 22.23 | |||||
EV-to-Forward-EBITDA | 13.32 | |||||
EV-to-Revenue | 3.25 | |||||
EV-to-Forward-Revenue | 3.26 | |||||
EV-to-FCF | 41.72 | |||||
Price-to-GF-Value | 1.76 | |||||
Price-to-Projected-FCF | 3.24 | |||||
Price-to-Median-PS-Value | 2.63 | |||||
Earnings Yield (Greenblatt) % | 2.74 | |||||
FCF Yield % | 3.15 | |||||
Forward Rate of Return (Yacktman) % | 3.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:TEVA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Teva Pharmaceutical Industries Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 17,314 | ||
| EPS (TTM) ($) | 0.6 | ||
| Beta | 0.7121 | ||
| 3-Year Sharpe Ratio | 1.18 | ||
| 3-Year Sortino Ratio | 2.46 | ||
| Volatility % | 38.75 | ||
| 14-Day RSI | 55.87 | ||
| 14-Day ATR ($) | 1.065511 | ||
| 20-Day SMA ($) | 36.91 | ||
| 12-1 Month Momentum % | 83.41 | ||
| 52-Week Range ($) | 18.21 - 38.37 | ||
| Shares Outstanding (Mil) | 1,165.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Teva Pharmaceutical Industries Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Teva Pharmaceutical Industries Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-03 | In 144 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-01-28 08:00 | In 139 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-28 07:00 | In 139 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 08:00 | In 55 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 07:00 | In 55 days | ||
| Guidance call for 2026 | 2026-09-23 05:05 | In 12 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 08:30 | In 3 days | ||
| IL-15 Celiac Disease Phase 2a Topline Results - Conference Call | 2026-09-02 08:00 | 36.19 (-0.90%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:00 | 31.67 (+1.57%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 31.67 (+1.57%) |
Show
Entries
Teva Pharmaceutical Industries Ltd Frequently Asked Questions
What is Teva Pharmaceutical Industries Ltd(TEVA)'s stock price today?
The current price of TEVA is $37.09. The 52 week high of TEVA is $38.37 and 52 week low is $18.21.
When is next earnings date of Teva Pharmaceutical Industries Ltd(TEVA)?
The next earnings date of Teva Pharmaceutical Industries Ltd(TEVA) is 2026-11-05 Est..
Does Teva Pharmaceutical Industries Ltd(TEVA) pay dividends? If so, how much?
Teva Pharmaceutical Industries Ltd(TEVA) does not pay dividend.
Press Release
Headlines
See More- 1
Sep 10, 2026
Teva prices $4.9B senior notes to refinance higher-cost debt
Seeking Alpha • 5:48am
Sep 07, 2026
Teva launches offering of senior notes to refinance existing debt
Seeking Alpha • 3:57am
Sep 02, 2026
Teva posts mid-stage trial win for celiac disease therapy developed with Royalty Pharma
Seeking Alpha • 6:34am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers